US FTC seeks additional info on Pfizer's proposed takeover of Seagen
Add BT as a preferred source
THE US Federal Trade Commission (FTC) has sought additional information and documentary material related to Pfizer’s proposed acquisition of Seagen Inc , Seagen said on Friday (Jul 14).
The antitrust agency sent the requests separately to both the companies, a regulatory filing said.
Pfizer struck a US$43 billion deal in March to acquire Seagen and its targeted cancer therapies to counter the fall in Covid-related sales and generic competition for some top-selling drugs.
The recent scrutiny by the antitrust agency to block Amgen’s US$27.8 billion deal to buy Horizon Therapeutics has made investors jittery around the Pfizer-Seagen deal as well.
Seagan continues to expect its merger with Pfizer will be completed in late 2023 or early 2024, it said in the filing. REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
CSE Global independent director quits after clashes with chairman Eugene Lai over board refresh
Cat A COE rate exceeds Cat B for third time in 4 months; premiums largely down
‘I felt like dying’: Thai Singha beer scion speaks up after disclosure of alleged sexual abuse
Manulife pulls loan product for rich Hong Kong clients after scrutiny
